Use of continuous subcutaneous insulin infusion pump in patients with type 2 diabetes mellitus

Diabetes Educator

Volumn 31, Issue 6, 2005, Pages 843-848

  Nielsen, Susan ^a   Kain, Donna ^a   Szudzik, Elizabeth ^a   Dhindsa, Sandeep ^a   Garg, Rajesh ^a   Dandona, Paresh ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BLOOD; CASE REPORT; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN INFUSION; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 28844452924     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/0145721705283078     Document Type: Article

References (13)

1. Dandona P, Foster M, Healey F, Greenbury E, Beckett AG. Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet. 1978;2:283-285.
2. Dandona P, Fonseca V, Fernando O, et al. Control of diabetes through a subcutaneous peritoneal access device (SPAD) in patients with resistance to subcutaneously injected insulin. Diabetes Res. 1987;5:47-49.
3. Paulsen EP, Courtney JW III, Duckworth WC. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes. 1979;28:640-645.
4. Soudan B, Girardot C, Fermon C, Verlet E, Pattou F, Vantyghem MC. Extreme subcutaneous insulin resistance: a misunderstood syndrome. Diabetes Metab. 2003;29:539-546.
5. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002;18(suppl 1):S14-S20.
6. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7:188-199.
7. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254-2264.
8. Chaudhuri A, Tomar R, Mohanty P, et al. The combination of insulin and metformin in treatment of non-insulin-dependent diabetes mellitus. Endocr Pract. 1998;4:259-267.
9. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab. 2000;11:362-368.
10. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
11. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985;28:119-121.
12. Maberly GF, Wait GA, Kilpatrick JA, et al. Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient. Diabetologia. 1982;23:333-336.
13. Schade DS, Duckworth WC. In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med. 1986;315:147-153.